New Dual-Target CAR t therapy aims to control multiple myeloma early
Disease control
Recruiting now
This early-phase study tests a new treatment called BMS-986453 for people recently diagnosed with multiple myeloma who are not planning a stem cell transplant. The therapy uses specially engineered immune cells to target two proteins on myeloma cells. The main goals are to check …
Phase: PHASE1 • Sponsor: Susan Bal • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC